Abstract

The development of prophylactic vaccines against HIV is of paramount importance in the global efforts to halt the spread of the virus. The Clinical Bioreagent Center (CBC) will be utilized in the production of clinical-grade vaccine candidates based on the viral envelope protein (EnV).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Inter-Agency Agreements (Y01)
Project #
AAI12021001-1-0-3
Application #
9127869
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2015
Total Cost
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code